Wockhardt Limited
WOCKPHARMA
Rang în acțiuni
#4516
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Preț acțiune
$21.04
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$3.42B
Schimbare (1 zi)
-2.39%
Schimbare (1 an)
38.07%
Țară
IN
Tranzacționează Wockhardt Limited (WOCKPHARMA)
Categorie
Healthcare
Raport P/S pentru Wockhardt Limited (WOCKPHARMA)
Raport P/S la data de October 2026 TTM: 8.92
Conform celor mai recente rapoarte financiare și prețului acțiunilor Wockhardt Limited, raportul P/S actual (TTM) este 8.92. La sfârșitul anului 2024, compania avea un P/S de 3.05.
Istoricul raportului P/S pentru Wockhardt Limited din 2004 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 8.92 | 20.16% |
| 2025 | 7.42 | 143.29% |
| 2024 | 3.05 | 264.90% |
| 2023 | 0.84 | -15.53% |
| 2022 | 0.99 | -46.30% |
| 2021 | 1.84 | 151.79% |
| 2020 | 0.73 | -44.52% |
| 2019 | 1.32 | -42.22% |
| 2018 | 2.28 | 6.29% |
| 2017 | 2.15 | -17.82% |
| 2016 | 2.62 | -47.40% |
| 2015 | 4.97 | 340.80% |
| 2014 | 1.13 | -73.70% |
| 2013 | 4.29 | 178.30% |
| 2012 | 1.54 | 50.46% |
| 2011 | 1.02 | 179.89% |
| 2010 | 0.37 | 1.87% |
| 2008 | 0.36 | -80.81% |
| 2007 | 1.87 | -22.86% |
| 2006 | 2.43 | -34.99% |
| 2005 | 3.73 | 10.06% |
| 2004 | 3.39 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.31 | 15.65% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 69.62% |
US
|
